No results for ‘’
Godavari Drugs Ltd
NSE: BSE: 530317
â‚ą101
(1%)
Tue, 25 Aug 2026, 09:00 pm
Market Cap (in Cr)102.29
PE Ratio19.92
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KGodavari Drugs Analysis
dividend
- Unable to evaluate Godavari Drugs's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Godavari Drugs's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Godavari Drugs is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Godavari Drugs is profitable, therefore cash runway is not a concern.
- Godavari Drugs is profitable, therefore cash runway is not a concern.
- Debt is covered by short term assets, assets are 2.3x debt.
- Godavari Drugs's cash and other short term assets cover its long term commitments.
- Debt is not well covered by operating cash flow (15.1%, less than 20% of total debt).
- The level of debt compared to net worth has increased over the past 5 years (31.5% vs 129.5% today).
- Interest payments on debt are not well covered by earnings (EBIT is 2x annual interest expense, ideally 3x coverage).
- Godavari Drugs's level of debt (129.5%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Godavari Drugs board of directors is about average.
- Mukund's remuneration is lower than average for companies of similar size in India.
- Mukund's compensation has been consistent with company performance over the past year, both up more than 20%.
misc
- Godavari Drugs is not covered by any analysts.
- Godavari Drugs has significant price volatility in the past 3 months.
past
- Godavari Drugs's 1-year earnings growth exceeds its 5-year average (36.1% vs -23.9%)
- Godavari Drugs's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (36.1% vs 22.7%).
- Godavari Drugs's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
- Godavari Drugs used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Godavari Drugs's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- Godavari Drugs has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
value
- Godavari Drugs is good value based on assets compared to the IN Pharmaceuticals industry average.
- Godavari Drugs is good value based on earnings compared to the IN Pharmaceuticals industry average.
- Godavari Drugs is good value based on earnings compared to the India market.
- BSE:530317 is up 19.4% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:530317 is up 19.4% outperforming the market in India which returned 8% over the past month.
- Godavari Drugs's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Godavari Drugs's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- 530317 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 530317 underperformed the Market in India which returned -14.5% over the past year.